| Literature DB >> 28168662 |
Yoichi Oshima1, Junichi Hoshino2, Tatsuya Suwabe2, Noriko Hayami2, Masayuki Yamanouchi2, Akinari Sekine2, Toshiharu Ueno2, Hiroki Mizuno2, Junko Yabuuchi2, Aya Imafuku2, Masahiro Kawada2, Rikako Hiramatsu2, Eiko Hasegawa2, Naoki Sawa2, Kenmei Takaichi2,3, Nobukazu Hayashi4, Takeshi Fujii5, Yoshifumi Ubara2,3.
Abstract
A 41-year-old man was referred to our hospital for the evaluation of hypergammaglobulinemia (IgG 2898 mg/dL and IgA 587 mg/dL), inflammation (CRP 6.7 mg/dL and serum interleukin-6 (IL-6) 15.1 ng/L), and anemia (Hb 10.9 mg/dL). Castleman's disease (CD) was diagnosed by axillary lymph node biopsy. Five months later, painful purpura (multiple palpable 5 mm lesions) developed on his legs, gradually spreading to the upper limbs, thighs, and trunk, accompanied by arthralgia of the wrists, ankles, and knees. Skin biopsy revealed leukocytoclastic vasculitis with IgA deposits in dermal vessels. Accordingly, IgA vasculitis (Henoch-Schönlein purpura) was diagnosed. Tocilizumab (an anti-IL-6 receptor antibody) was administered intravenously at 8 mg/kg and treatment was repeated at monthly intervals. His purpura and clinical findings specific to CD improved rapidly. CD is well known to cause various skin lesions. The findings in this case indicate that overproduction of IL-6 contributes to IgA vasculitis (Henoch-Schönlein purpura) as well as to the pathogenesis of CD.Entities:
Keywords: Castleman’s disease; Henoch-Schönlein purpura; IgA vasculitis; Interleukin-6; Leukocytoclastic vasculitis; Tocilizumab
Mesh:
Substances:
Year: 2017 PMID: 28168662 DOI: 10.1007/s10067-017-3568-y
Source DB: PubMed Journal: Clin Rheumatol ISSN: 0770-3198 Impact factor: 3.650